Development of a scoring system for predicting the severity of ulcerative colitis.

[1]  K. Mitsuyama,et al.  Role of Serum Proteinase 3 Antineutrophil Cytoplasmic Antibodies in the Diagnosis, Evaluation of Disease Severity, and Clinical Course of Ulcerative Colitis , 2021, Gut and liver.

[2]  Hongjie Zhang,et al.  Combination of serological biomarkers and clinical features to predict mucosal healing in Crohn’s disease: a multicenter cohort study , 2021, BMC Gastroenterology.

[3]  L. Peyrin-Biroulet,et al.  A practical guide for faecal calprotectin measurement: myths and realities. , 2020, Journal of Crohn's & colitis.

[4]  Ran Ma,et al.  IL-10 enhances T cell survival and is associated with faster relapse in patients with inactive ulcerative colitis. , 2020, Molecular immunology.

[5]  K. Goda,et al.  Endoscopic score vs blood cell indices for determining timing of immunomodulator withdrawal in quiescent ulcerative colitis , 2019, Scientific Reports.

[6]  M. Karsdal,et al.  Serological Assessment of the Quality of Wound Healing Processes in Crohn's Disease. , 2019, Journal of gastrointestinal and liver diseases : JGLD.

[7]  P. de Vos,et al.  A Combined Set of Four Serum Inflammatory Biomarkers Reliably Predicts Endoscopic Disease Activity in Inflammatory Bowel Disease , 2019, Front. Med..

[8]  A. Lucendo,et al.  Fecal calprotectin is not superior to serum C-reactive protein or the Harvey–Bradshaw index in predicting postoperative endoscopic recurrence in Crohn’s disease , 2018, European journal of gastroenterology & hepatology.

[9]  K. Mitsuyama,et al.  Diagnostic and clinical role of serum proteinase 3 antineutrophil cytoplasmic antibodies in inflammatory bowel disease , 2018, Journal of gastroenterology and hepatology.

[10]  S. Travis,et al.  Limited uptake of ulcerative colitis “treat‐to‐target” recommendations in real‐world practice , 2018, Journal of gastroenterology and hepatology.

[11]  Dhruvan Patel,et al.  Management of Anemia in Patients with Inflammatory Bowel Disease (IBD) , 2018, Current Treatment Options in Gastroenterology.

[12]  L. Dieleman,et al.  Within-Stool and Within-Day Sample Variability of Fecal Calprotectin in Patients With Inflammatory Bowel Disease: A Prospective Observational Study , 2016, Journal of clinical gastroenterology.

[13]  J. Korzenik,et al.  Blood-based Biomarkers Used to Predict Disease Activity in Crohn's Disease and Ulcerative Colitis , 2015, Inflammatory bowel diseases.

[14]  R. Gearry,et al.  Disease Activity Assessment in IBD: Clinical Indices and Biomarkers Fail to Predict Endoscopic Remission , 2015, Inflammatory bowel diseases.

[15]  M. Vietri,et al.  Laboratory markers in ulcerative colitis: Current insights and future advances. , 2015, World journal of gastrointestinal pathophysiology.

[16]  C. Çekiç,et al.  An Evaluation of the Correlation between Hepcidin Serum Levels and Disease Activity in Inflammatory Bowel Disease , 2015, Gastroenterology research and practice.

[17]  D. Altman,et al.  Reliability and initial validation of the ulcerative colitis endoscopic index of severity. , 2013, Gastroenterology.

[18]  A. Forbes,et al.  PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[19]  E. Cotte,et al.  Neopterin Is a Novel Reliable Fecal Marker as Accurate as Calprotectin for Predicting Endoscopic Disease Activity in Patients with Inflammatory Bowel Diseases , 2013, Inflammatory bowel diseases.

[20]  S. Ng,et al.  Serological Antibodies in Inflammatory Bowel Disease: A Systematic Review , 2012, Inflammatory bowel diseases.

[21]  Z. Tulassay,et al.  The Role of Autoantibodies in Inflammatory Bowel Disease , 2012, Digestive Diseases.

[22]  M. Ciorba,et al.  Biomarkers in inflammatory bowel disease: current practices and recent advances. , 2012, Translational research : the journal of laboratory and clinical medicine.

[23]  K. Tsiveriotis,et al.  Antineutrophil Cytoplasmic Antibodies Testing in a Large Cohort of Unselected Greek Patients , 2011, Autoimmune diseases.

[24]  J. Savige,et al.  Evaluation of a multiplex flow cytometric immunoassay to detect PR3- and MPO-ANCA in active and treated vasculitis, and in inflammatory bowel disease (IBD). , 2008, Journal of immunological methods.

[25]  J. Dent,et al.  The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus , 2006, The American Journal of Gastroenterology.

[26]  C. Kallenberg,et al.  Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis. , 2002, Journal of the American Society of Nephrology : JASN.

[27]  A. Wiik.  What you should know about PR3-ANCA: An introduction , 2000, Arthritis research.

[28]  B. Vainer,et al.  Established and emerging biological activity markers of inflammatory bowel disease. , 2000, The American journal of gastroenterology.

[29]  A. Kaser,et al.  Inflammatory bowel disease. , 2010, Annual review of immunology.

[30]  Malfertheiner,et al.  World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. , 2010, Inflammatory bowel diseases.